Early Pharmacodynamic Effects of Exenatide Once Weekly in Type 2 Diabetes Are Independent of Weight Loss: A Pooled Analysis of Patient-level Data  by Trautmann, Michael E. et al.
Clinical Therapeutics/Volume 38, Number 6, 2016Early Pharmacodynamic Effects of Exenatide Once
Weekly in Type 2 Diabetes Are Independent of
Weight Loss: A Pooled Analysis of Patient-level DataMichael E. Trautmann, MD1; Jenny Han, MS2; and James Ruggles, PhD3
1Diabetes Research Hamburg, Hamburg, Germany; 2Pharmapace, Inc, San Diego, California;
and 3AstraZeneca, Fort Washington, PennsylvaniaAccepted for publication March 30, 2016.
http://dx.doi.org/10.1016/j.clinthera.2016.03.039
0149-2918/$ - see front matter
& 2016 The Authors. Published by Elsevier HS Journals, Inc. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).ABSTRACT
Purpose: Exenatide once weekly, a glucagon-like
peptide-1 receptor agonist (GLP-1RA), is approved as
an adjunct to diet and exercise for the treatment of
adults with type 2 diabetes mellitus. Exenatide acts by
binding to and activating glucagon-like peptide-1
receptors, thereby stimulating glucose-dependent in-
sulin secretion, suppressing glucose-dependent gluca-
gon secretion, slowing gastric emptying, and
increasing feelings of satiety. Gradual increases in
drug level (“autotitration”) after the initiation of a
ﬁxed exenatide 2-mg weekly dose achieve minimal
effective (50 pg/mL) and steady-state (300 pg/mL)
concentrations by 2 weeks and 6 to 8 weeks, respec-
tively. The purpose of this study was to examine
pharmacodynamic outcomes with exenatide once
weekly and to determine whether changes are secon-
dary to weight loss and thus delayed by the sequential
nature of responses.
Methods: This post hoc analysis evaluated trials in
the exenatide once-weekly development program.
Outcomes included glycosylated hemoglobin (HbA1c),
weight, fasting serum or plasma glucose (FG), lipids,
and blood pressure (BP) at weeks 2, 4, and 24.
Relationships between changes from baseline in these
outcomes and changes in weight were examined. The
effect of nausea and vomiting (adverse events charac-
teristic of GLP-1RAs) on weight loss was also
assessed.
Findings: Pooled data were analyzed from 12 trials
in which 2190 patients received exenatide once
weekly. Patients had a mean HbA1c level of 8.4%
and weight of 87 kg at baseline. Exenatide once
weekly produced signiﬁcant improvements in HbA1c,
FG, weight, and systolic BP at weeks 2 and 4, with
continuous improvements through week 24. There
were no clinically meaningful correlations between1464weight loss and improvements in pharmacodynamic
outcomes at weeks 2, 4, or 24. Patients had signiﬁcant
reductions in weight at weeks 2, 4, and 24 regardless
of whether they experienced nausea and/or vomiting
during the study, although patients with at least
1 nausea/vomiting event had greater weight loss at
week 24 than those who did not.
Implications: Improvements in pharmacodynamic
end points occurred early in treatment with exenatide
once weekly, before steady-state plasma concentra-
tions. These early effects did not seem to be secondary
to weight loss and are likely the direct effects of
exenatide. (Clin Ther. 2016;38:1464–1473) & 2016
The Authors. Published by Elsevier HS Journals, Inc.
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enatide, glucagon-like peptide-1 receptor agonist,
HbA1c, pharmacokinetics.INTRODUCTION
Sustained metabolic control has been shown to minimize
complications in type 2 diabetes mellitus (T2DM). How-
ever, reduction in hyperglycemia early after treatment
initiation is reassuring to physicians and patients, provid-
ing evidence that the chosen therapy is effective. Thus,
treatment is also geared toward rapid reduction in
hyperglycemia and control of cardiometabolic risk factors
such as lipids and blood pressure (BP).
Although long-term glycemic control is import-
ant to prevent complications of T2DM, a rapid
response to therapy is also reassuring to physiciansVolume 38 Number 6
M.E. Trautmann et al.and patients. Early response helps build patients’
conﬁdence that the medication is working, and pa-
tients’ perception that the treatment is worthwhile
may help empower them to continue therapy.1
However, because T2DM is a chronic disease, the
use of therapies that deliver robust responses which
are sustained over the long term is of greater beneﬁt to
patients than a rapid response. Moreover, having
realistic expectations about the timing of anticipated
therapeutic beneﬁts is important to prevent wrong
treatment decisions such as premature switching of
treatment. Exenatide once weekly has demonstrated
durable long-term beneﬁts, with glucose-lowering
effects sustained for several years in long-term stud-
ies.2,3 Compared with the time course of response to
thiazolidinediones and dipeptidyl peptidase-4 inhibi-
tors, glycemic and weight responses with exenatide
once weekly have been shown to occur early after
treatment initiation.4,5 However, because exenatide
once-weekly microspheres release exenatide gradually,
there has been a perception that the onset of efﬁcacy
may be too slow and that the efﬁcacy may be
dependent on weight loss. Therefore, more informa-
tion is needed about the rate of onset of exenatide
once-weekly therapy, and establishing whether there is
a correlation between weight loss and early therapeu-
tic outcomes is of crucial interest.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs)
are injectable glucose-lowering medications approved
as an adjunct to diet and exercise for the treatment of
adults with T2DM. Agents in the GLP-1RA class bind to
and activate glucagon-like peptide-1 (GLP-1) receptors,
thereby producing effects similar to those of endo-
genous GLP-1, including stimulating glucose-dependent
insulin secretion, suppressing glucose-dependent glucagon
secretion, slowing gastric emptying, and increasing
feelings of satiety.6 Because these agents act by
supplementing endogenous GLP-1 activity, treatment
with high concentrations of GLP-1RAs can produce
stronger effects compared with dipeptidyl peptidase-4
inhibitors, which act by inhibiting proteolytic cleavage
of endogenous GLP-1 and produce only 2- to 3-fold
increases in plasma GLP-1 concentrations.7 GLP-1RAs
offer effective glycemic control with the added beneﬁts of
weight loss, a low risk of hypoglycemia, and positive
effects on cardiovascular risk factors.1
Exenatide is a GLP-1RA that is available for admin-
istration as a BID and a once-weekly formulation. In the
once-weekly formulation, exenatide is encapsulated inJune 2016poly-(D, L-lactide-co-glycolide) microspheres and re-
leased from these microspheres in a 3-stage process
(initial release, diffusion release, and erosion release),
resulting in continuous delivery of exenatide.8 Due to
the long release of exenatide from the microsphere
depots for up to 10 weeks, drug concentrations
accumulate with subsequent injections. Exenatide once
weekly achieves the minimal effective concentration
(50 pg/mL) for glucose lowering with regular once-
weekly dosing in 2 weeks, and steady-state plasma
concentrations (300 pg/mL) are reached in 6 to 8
weeks.9–12 Gradual dose escalation of exenatide has
been shown to improve gastrointestinal tolerability.13
Therefore, most GLP-1RAs are initiated at a low dose,
with subsequent dose increases to improve tolerability
(“titration”). With exenatide once-weekly administra-
tion, the concentration of exenatide increases with
autotitration and reaches steady-state plasma levels in
6 to 8 weeks, and the risk of gastrointestinal adverse
events has been found to be reduced compared with
BID dosing.8 Understanding the balance between the
robust and sustained effects of exenatide once weekly
and tolerability during initiation of therapy is an
important consideration for patients and health care
providers.
In randomized controlled studies of 24 to 30 weeks
and extensions up to 6 years, exenatide once weekly
has been shown to improve glycemic control, reduce
excess body weight, and improve cardiovascular risk
markers, including BP and lipids.2,14,15 However, the
time courses of these changes may not be identical.
Because glycemic control and cardiovascular risk
markers can be improved by weight loss alone, the
relationship of weight loss with efﬁcacy outcomes is of
interest.
The current post hoc analysis was designed to: (1)
characterize the early therapeutic response to exena-
tide once weekly and thus inform patient and physi-
cian expectations for clinical practice; and (2) examine
whether early improvements in pharmacodynamic
outcomes are secondary to weight loss or are direct
effects.PATIENTS AND METHODS
This post hoc analysis considered pooled data from
11 randomized, placebo- or active comparator–con-
trolled trials and 1 single-arm study from the exenatide
once-weekly development program. Pharmacodynamic1465
Table I. Demographic and baseline characteristics.
Characteristic
Pooled Analysis
Population
(N ¼ 2190)
Age, y* 55 (10)
Male, no. (%) 1241 (56.7)
Race/ethnicity, no. (%)
White 1128 (51.5)
Asian 723 (33.0)
Black 63 (2.9)
Hispanic 271 (12.4)
Other 5 (0.2)
Duration of diabetes, y* 7 (6)
Weight, kg* 87.1 (20.8)
Body mass index, kg/m2* n ¼ 2180 31.1 (5.8)
Glycosylated hemoglobin, % n ¼ 2188 8.4 (1.1)
Fasting glucose, mmol/L* n ¼ 2146 9.4 (2.6)
HDL-C, mmol/L* n ¼ 2099 1.2 (0.3)
LDL-C, mmol/L* n ¼ 2099 2.6 (0.9)
Total cholesterol, mmol/L* n ¼ 2130 4.7 (1.1)
Triglycerides, mmol/L* n ¼ 2153 2.1 (1.5)
Systolic blood pressure,
mm Hg*
130.6 (14.5)
Diastolic blood pressure,
mm Hg*
78.8 (9.0)
Glucose-lowering
background
therapy, no. (%)†
Metformin 822 (37.5)
Sulfonylurea 58 (2.6)
Thiazolidinedione 26 (1.2)
Clinical Therapeuticsoutcomes were deﬁned after 2, 4, and 24 weeks of
exenatide once-weekly treatment, and the correlations
between changes in these outcomes and weight loss were
examined. The relationship between the occurrence of
nausea and vomiting (adverse events characteristic of the
GLP-1RA class) and weight loss was also assessed.
Detailed information on study designs and patient
eligibility for individual trials has been published
previously.4,5,11,16–24 In these studies, patients with
T2DM received exenatide once weekly as monother-
apy or as an add-on to metformin, a sulfonylurea, or a
thiazolidinedione for treatment durations of 10 to
52 weeks.
Statistical Analyses
Descriptive statistics were used to report baseline
demographic characteristics and patient characteris-
tics, with continuous variables described as mean
(SD). Pharmacodynamic outcomes assessed included
glycosylated hemoglobin (HbA1c), fasting glucose
(FG; determined from plasma or serum), weight, lipids
(total cholesterol, LDL-C, and HDL-C, and triglycer-
ides), and BP. For each outcome, the mean (SE)
change from baseline was calculated at weeks 2, 4,
and 24. Ninety-ﬁve percent CIs for the mean changes
from baseline at each time point were derived, and an
inference on statistical signiﬁcance at α = 0.05 level
was made. For each outcome, the proportion of
patients achieving any amount of improvement
(ie, change from baseline 40 for HDL-C or o0 for
other outcomes) was calculated for patients with
available measurements at weeks 2, 4, and 24.
Changes from baseline in body weight (mean [SE]
and 95% CI) were also calculated at weeks 2, 4, and
24 for patients who experienced at least 1 nausea or
vomiting event during the study period and for those
who did not.
The association between change from baseline for
each outcome and change from baseline in body weight
was examined by using the Pearson coefﬁcient of
correlation (r) at each time point (weeks 2, 4, and 24).Dual therapy 944 (43.1)
Triple therapy 27 (1.2)
None 311 (14.2)
*Mean (SD).
†Insulin and quadruple therapy were used in 1 patient
each (o0.1%).RESULTS
Patient Demographic and Baseline
Characteristics
The pooled analysis included 2190 patients treated
with exenatide once weekly in 12 clinical trials. At
baseline, patients had a mean age of 55 years, and146656.7% were male (Table I). Patients had a mean
HbA1c level of 8.4% and weight of 87.1 kg; the mean
duration of diabetes was 7 years.
Efficacy at Weeks 2, 4, and 24
Exenatide once weekly resulted in statistically sig-
niﬁcant improvements from baseline in HbA1c, FG,Volume 38 Number 6
M.E. Trautmann et al.weight, and systolic BP by weeks 2 and 4, and further
improvements were observed at week 24.
There were modest but statistically signiﬁcant
reductions from baseline in HbA1c levels at weeks 2
and 4 (–0.3% and –0.4%, respectively); by week 24,
the mean (SE) change from baseline in HbA1c was
1.4% (0.03%) (P o 0.05) (Figure 1A). At weeks 2
and 24, 70.8% and 91.5% of patients, respectively,
had reductions in HbA1c (Figure 2).
FG decreased from baseline by week 2 (mean [SE]
change, 0.9 [0.1] mmol/L; P o 0.05) and continued
to decrease, with a change at week 4 of 1.6 (0.1)
mmol/L (Po 0.05) and a ﬁnal change from baseline at
week 24 of 2.1 (0.1) mmol/L (Po 0.05) (Figure 1B).
At weeks 2 and 24, 75.2% and 84.3% of patients,
respectively, had reductions in FG (Figure 2).
At weeks 2, 4, and 24, 55.5%, 61.5%, and 74.4%
of patients, respectively, had reductions in weight
(Figure 2). Initial early weight loss was 0.3 kg at
week 2 and 0.6 kg at week 4; by week 24, the
mean (SE) change in weight was 2.4 (0.08) kg (all,
P o 0.05 vs baseline) (Figure 1C).0.0
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Figure 1. Mean (SE) changes from baseline in (A) glycos
from plasma or serum, (C) weight, and (
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June 2016There were small reductions from baseline in total
cholesterol and LDL-C at each time point, which were
statistically signiﬁcant (P o 0.05) at weeks 4 and 24
(Table II). However, there was no signiﬁcant change
from baseline in HDL-C or triglyceride levels at any
time point. At weeks 2, 4, and 24, approximately one
half of patients had improvements in lipid parameters
(Figure 2).
Signiﬁcant reductions in systolic BP were apparent
at weeks 2 and 4, and systolic BP continued to
decrease over 24 weeks (Figure 1D). There were
lesser reductions in diastolic BP at each time point.
At week 2, 51.1% of patients had some degree of
reduction in systolic BP, with the proportion
increasing slightly to 54.9% at week 24 (Figure 2).
Correlations Between Efficacy Outcomes and
Weight Loss
There were no clinically meaningful correlations
observed between weight loss and changes in HbA1c,
FG, and systolic BP at weeks 2, 4, and 24 (rr 0.1489)
(Figures 3A–3C). There were also no signiﬁcant–3
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patients for whom data were available for this parameter at each time point. DBP ¼ diastolic blood
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Clinical Therapeuticscorrelations between weight loss and changes in
diastolic BP, HDL-C, LDL-C, total cholesterol, or
triglycerides at weeks 2, 4, or 24.
Effect of Nausea and Vomiting on Weight Loss
Nausea and vomiting events occurred in 4.0% to
7.0% and 0.7% to 2.0% of patients, respectively, during
any 2-week interval between baseline and week 24.
Signiﬁcant reductions in weight from baseline occurred
at weeks 2, 4, and 24, regardless of whether patients
experienced nausea/vomiting (Figure 4). However,
patients who experienced at least 1 nausea/vomitingTable II. Change from baseline in lipid levels. Data are
Outcome Week 2
LDL-C, mmol/L n ¼ 60
0.0 (0.06)
HDL-C, mmol/L n ¼ 60
0.0 (0.02)
Total cholesterol, mmol/L n ¼ 91
–0.1 (0.06)
Triglycerides, mmol/L,
median (IQR)
n ¼ 108
–0.07 (–0.73 to 0.30)
IQR ¼ interquartile range.
*P o 0.05 versus baseline.
1468event had greater weight loss at week 24 than those with
no events (–3.1 vs –2.2 kg; P o 0.05).DISCUSSION
In this pooled analysis, exenatide once weekly resulted
in signiﬁcant improvements in HbA1c, FG, weight,
and systolic BP by weeks 2 and 4, and further
improvements were observed at week 24. Further-
more, approximately one half of the patients achieved
improvements in lipid parameters at weeks 2, 4, and
24. The time to therapeutic response with exenatidemean (SE) unless noted otherwise.
Week 4 Week 24
n ¼ 222
–0.1 (0.03)*
n ¼ 1736
–0.1 (0.02)*
n ¼ 223
0.0 (0.01)
n ¼ 1737
0 (0)
n ¼ 254
–0.2 (0.04)*
n ¼ 1737
–0.2 (0.02)*
n ¼ 272
–0.04 (–0.46 to 0.36)
n ¼ 1753
–0.07 (–0.46 to 0.30)
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M.E. Trautmann et al.once weekly in this analysis was comparable with
those seen with pioglitazone,5,25 rosiglitazone,26 and
metformin5; for each of these agents, reductions in
glycemic parameters were observed soon after
treatment initiation, with the full effect achieved
after 2 to 3 months with dose titrations.June 2016Improvements in glycemic outcomes did not corre-
late with weight loss at the studied time points. This
ﬁnding suggests that improvements were likely due to a
direct effect of exenatide. Early improvements in
glycemic control are consistent with the pharmacoki-
netics of exenatide once weekly, whereby the minimally1469
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weight in patients with and without
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Clinical Therapeuticseffective concentration (50 pg/mL) for reducing FG
levels is exceeded within 2 weeks and steady-state
concentrations are achieved in 6 to 8 weeks.10
It has been postulated that greater weight loss is
related to nausea and vomiting among some patients
receiving GLP-1RA therapy. In the current analysis,
patients who experienced nausea/vomiting had signiﬁ-
cantly greater weight loss than those with no nausea/
vomiting at week 24. However, both groups had
signiﬁcant reductions in weight with exenatide once-
weekly treatment at weeks 2, 4, and 24. These
ﬁndings concur with those of a post hoc analysis of
pooled data from 3 trials (DURATION-1 [Diabetes
Therapy Utilization: Researching Changes in A1C,
Weight and Other Factors Through Intervention with
Exenatide Once Weekly], DURATION-5, and
NCT00917267) and a separate analysis of the
DURATION-6 trial.27 In these analyses, reductions
in weight after 26 weeks of treatment with exenatide
once weekly occurred in patients with no
gastrointestinal adverse events; however, reductions
were signiﬁcantly greater for patients with upper
gastrointestinal events compared with patients with
no gastrointestinal events.
The current results suggest that clinical efﬁcacy,
including glycemic effects, of exenatide once weekly
occurs well before steady-state plasma concentra-
tions are achieved, with effects seen from week 21470onward. Similarly, a recent post hoc analysis of the
DURATION-5 trial demonstrated that improvements
in HbA1c, FG, and weight occurred by week 4, before
exenatide concentrations reached steady state.28
Although small weight reductions were apparent
early after treatment initiation (at weeks 2 and 4) in
the DURATION-5 trial, weight reductions occurred
more gradually than glycemic responses, consistent
with the current results. The results from the current
analysis are also in line with modeling analyses of
exenatide once weekly, showing that weight reductions
occurred at a higher exenatide plasma concentration
(change in weight half-maximal effective concentration,
184 pg/mL) compared with changes in FG (change
in weight half-maximal effective concentration,
57 pg/mL).10 Thus, weight loss with exenatide exposure
may be expected to lag behind reductions in FG.
The ﬁndings of the current study are also in
accordance with those of another recently published
pooled analysis of clinical trials.29 The analysis
included 1830 patients treated with exenatide once
weekly, in which improvements in glycemic and
cardiovascular parameters were independent of
changes in weight; however, the analysis found that
the magnitude of improvements increased with higher
degrees of weight loss. It is possible that weight loss
enhances efﬁcacy over longer durations of therapy.
Exenatide once weekly has demonstrated sustained
efﬁcacy in an extension of the DURATION-1 trial and
in 3-year data from the randomized controlled
DURATION-3 trial.2,3 In the DURATION-1 trial,
reductions in HbA1c levels with exenatide once weekly
were maintained for up to 5 years in published
studies, with recent data showing sustained reductions
at 6 years (least squares mean reduction of 1.6% at
both 5- and 6-year follow-up).3,15 After 5 years,
signiﬁcant improvements were also observed for FG
(1.6 mmol/L), weight (3 kg), lipids, and diastolic
BP.3 Compared with titrated insulin glargine, exenatide
once weekly achieved and maintained signiﬁcantly
greater reductions in HbA1c and FG over 3 years of
follow-up in the DURATION-3 trial.2 Reductions in
weight, lipids, and BP were also sustained after 3 years
of treatment with exenatide once weekly.
Improving cardiovascular biomarkers is an impor-
tant goal in managing T2DM, as controlling cardio-
vascular risk factors has been shown to prevent or
slow cardiovascular disease in patients with T2DM.30
Furthermore, long-term, intensiﬁed interventionsVolume 38 Number 6
M.E. Trautmann et al.aimed at multiple cardiovascular risk factors have
been shown to reduce cardiovascular and micro-
vascular events by 50%.31 Thus, glucose-lowering
agents with the potential to improve cardiovascular
risk markers provide additional beneﬁts beyond
glycemic control. In this post hoc analysis, improve-
ments in some cardiovascular risk factors with
exenatide once weekly were minimal but may con-
tribute to the overall goal of reducing cardiovascular
risk in these patients.
Overall, this study included data from a large
number of patients across 12 clinical trials. Analyzing
clinical trial data provides the advantage of system-
atically collected and measured patient data, which
can be difﬁcult to collect in a real-world setting.
Improvements in glycemic control and other pharma-
codynamics outcomes are also associated with weight
loss, and the range of data collected in the clinical
trials permitted analysis of whether any of the ob-
served changes correlated with changes in weight from
baseline. The study also carries the limitations inher-
ent to post hoc pooled analyses in that these analyses
were not speciﬁed at the time the included clinical
trials were designed; thus, data were not necessarily
collected for the full study population for every end
point and assessment time or using uniform methods.
In addition, some studies were open-label due to the
different delivery of comparator agents (ie, oral vs
injectable). Another limitation is the absence of data
exploration for comparator treatments, which could
limit the interpretation of the results. Furthermore, for
most outcomes except weight and BP, the number of
patients with measures at week 2 was relatively
smaller, with larger numbers seen at the week 4 and
week 24 analyses. Another limitation was the inclu-
sion of nonuniform studies in the analysis. One study
included only treatment-naive patients,5,20 3 included
both treatment-naive and treatment-experienced pa-
tients,11,16,20 and the remainder required patients to
have experience with at least 1 other glucose-lowering
therapy. A limitation of the correlation analyses was
that the range of changes was narrow, making it more
difﬁcult to identify a linear correlation.CONCLUSIONS
This post hoc analysis showed that exenatide once-
weekly treatment demonstrated early, statistically sig-
niﬁcant improvements in glycemia, weight, andJune 2016systolic BP, documenting the onset of effects before
steady-state plasma exenatide concentrations, and that
improvements in clinical outcomes were not correlated
with weight loss. These ﬁndings suggest that exenatide
once weekly exerts direct actions on glycemic out-
comes and systolic BP within the ﬁrst 2 to 4 weeks of
treatment. The multiple actions of exenatide may
assist patients with T2DM in reaching the various
goals recommended by international associations.ACKNOWLEDGMENTS
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